作者
Solveig Landt, Sophia Jeschke, Angela Koeninger, Anke Thomas, Till Heusner, Susanne Korlach, Kurt Ulm, Peter Schmidt, Jens-Uwe Blohmer, Werner Lichtenegger, Jalid Sehouli, Sherko Kuemmel
发表日期
2010/2/1
期刊
Anticancer research
卷号
30
期号
2
页码范围
375-381
出版商
International Institute of Anticancer Research
简介
The aim of this study was to investigate the diagnostic value of tumor M2 pyrurate kinase (Tu-M2-PK) as a tumor marker in patients with pre-invasive (CIN), invasive (PCC) and recurrent (RCC) cervical cancer.
Materials and Methods
Plasma samples were investigated from 125 patients, comprising 50 cases of CIN (I-III), 51 of PCC (FIGO I-IV) and 24 of RCC, before treatment. Tu-M2-PK levels were determined by using a quantitative sandwich enzyme immunoassay. Results
With the increase in disease severity from CIN to PCC to RCC, levels of Tu-M2-PK significantly increased (p<0.001). Levels of Tu-M2-PK significantly increased with respect to the FIGO stage (p<0.001) and had significantly higher values in node+ patients (p=0.028). There was no significant difference in Tu-M2-PK levels in CIN I-III patients (p=0.626). Patients with distant metastasis had significantly elevated levels of Tu-M2-PK (p<0.001 …学术搜索中的文章
S Landt, S Jeschke, A Koeninger, A Thomas… - Anticancer research, 2010